BrainsWay Deep TMS™ for Late-Life Depression

Late-Life Depression

The only TMS system FDA-cleared to treat depression among patients ages 68-86 years.

Treating Depression in the Elderly Can Present Challenges Which May Limit the Efficacy of Traditional Treatment Options

- Elderly patients generally show higher non-response rates to antidepressants, up to 55%, which may be due to age-related changes in their brains.
- Multiple chronic conditions and numerous medications increase drug-drug interaction risks in older adults.
- ECT's invasive nature and cognitive side effects make it less tolerable for elderly patients.
- Shrinking social networks due to aging can worsen depressive symptoms and impede treatment.

BrainsWay®

www.brainsway.com

BrainsWay Deep TMS Technology is Particularly Suited for Treatment of Late-Life Depression

Deep TMS has unique features that can address limitations of existing depression treatments

- Clinically proven to help elderly patients who do not respond to medication or psychotherapy.
- Can reach deeper brain structures than traditional TMS, addressing the issue of increased scalp-cortex distance in elderly patients. This capability may enhance the likelihood of achieving therapeutic benefits in regions affected by age-related atrophy.



Skull to Cortex Distance Increases with Age

- Has no systemic side effects, drug-drug interactions associated with medication, or short-term memory loss associated with ECT.

Deep TMS Targets Depression-Related Brain Regions with H1 Coil Technology

- Treatment targets neural circuits associated with motivation and reward. The H1 Coil activates both the left and right prefrontal cortex, with a primary emphasis on the left dorsolateral prefrontal cortex (DLPFC).

BrainsWay Deep TMS has Demonstrated Safety and Efficacy in Reducing Depression Symptoms Among Elderly Patients, as Shown in Sham-Controlled Clinical Research and Real-World Clinical Practice

- In real clinical practice settings, the majority of treatment-resistant depression patients aged 60-91 have benefited from Deep TMS.[1]
- Among patients who completed at least 30 sessions, approximately 4 in 5 achieved response and approximately 3 in 5 achieved remission.



- The median onset of response was 14 sessions (20 days), and for remission, 15 sessions (23 days).
- Response rates, remission rates, and the median number of sessions/days required to reach response/remission were comparable to those seen in a large naturalistic study of Deep TMS in middle-aged adults with Major Depressive Disorder.

[1]Note, FDA late life labeling expansion extends to age 86, not 91.

Deep TMS's Unique Advantage in Treating Depression in Elderly Patients Allows You to Reach a Wider Segment of Your Community

BrainsWay's Practice Development Consultants work closely with you to build data-driven patient lead strategies and optimize practice workflow, helping ensure a strong return-on-investment.

Learn more about offering Deep TMS treatment for Late-Life Depression in your practice

- ☑ **SPEAK** with a **BrainsWay representative**
- ☑ **SCAN** the **QR code** for more information
- ☑ **VISIT** the Knowledge Center at **www.brainsway.com**
- ☑ **CALL** us at **844-386-7001**
- ☑ **EMAIL** us at **DeepTMS@brainsway.com**

SCAN ME

INDICATION: BrainsWay Deep TMS is indicated by the FDA for the treatment of depressive episodes and for decreasing Anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. FDA 510(k) No. K222196. No. K122288. No. K210201

SAFETY INFORMATION: Patients should consult with their doctor before undergoing BrainsWay Deep TMS. The most common side effects include headaches and application site pain or discomfort. There is also a very rare risk of seizure associated with the treatment. Patients with metal in or around the head as in metal plates, implants, and stents should not undergo Deep TMS treatment.

REFERENCES:

Tedeschini E, et al. Efficacy of Antidepressants for Late-Life Depression: A Meta-Analysis and Meta-Regression of Placebo-Controlled Randomized Trials. J Clin Psychiatry 2011;72(12):1660-1668

Blumberger, D.M., et al. A Review of Brain Stimulation Treatments for Late-Life Depression. Curr Treat Options Psych 2, 413–421 (2015).

Kozel FA, et al. How coil-cortex distance relates to age, motor threshold, and antidepressant response to repetitive transcranial magnetic stimulation. J Neuropsychiatry Clin Neurosci. 2000 Summer; 12(3):376-84.

Roth Y, et al. Never Too Late: Safety and Efficacy of Deep TMS for Late-Life Depression. Journal of Clinical Medicine. 2024; 13(3):816

Tendler A, et al. Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis. Psychiatry Research. Vol 324, June 2023, 115179

Kaster, T.S., et al. Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacol 43, 2231–2238 (2018)

BrainsWay®

www.brainsway.com

BW-MDD-27 rev. 06/2024